Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Kuter DJ"" wg kryterium: Autor


Tytuł:
Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
Autorzy:
Ventura P; Department of Surgical and Medical Sciences for Children and Adults, Internal Medicine Unit, University of Modena and Reggio Emilia, Modena, Italy.
Bonkovsky HL; Section on Gastroenterology and Hepatology, Wake Forest University/North Carolina Baptist Medical Center, Winston-Salem, NC, USA.
Gouya L; Centre Français des Porphyries, Paris, France.
Aguilera-Peiró P; Hospital Clinic Barcelona, Barcelona, Spain.
Montgomery Bissell D; UCSF Liver Center and Porphyria Center, University of California, San Francisco, CA, USA.
Stein PE; King's College Hospital, London, UK.
Balwani M; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Anderson DKE; University of Texas Medical Branch, Galveston, TX, USA.
Parker C; University of Utah, Salt Lake City, UT, USA.
Kuter DJ; Center for Hematology, Massachusetts General Hospital, Boston, MA, USA.
Monroy S; Instituto Nacional de Pediatría, Mexico City, Mexico.
Oh J; Konkuk University Medical Center, Seoul, South Korea.
Ritchie B; University of Alberta Hospital, Edmonton, Canada.
Ko JJ; Alnylam Pharmaceuticals, Cambridge, MA, USA.
Hua Z; Alnylam Pharmaceuticals, Cambridge, MA, USA.
Sweetser MT; Alnylam Pharmaceuticals, Cambridge, MA, USA.
Sardh E; Porphyria Centre Sweden, Centre for Inherited Metabolic Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Pokaż więcej
Corporate Authors:
ENVISION Investigators
Źródło:
Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2022 Jan; Vol. 42 (1), pp. 161-172. Date of Electronic Publication: 2021 Nov 16.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Porphyria, Acute Intermittent*/chemically induced
Porphyria, Acute Intermittent*/drug therapy
Porphyrias, Hepatic*/chemically induced
Porphyrias, Hepatic*/drug therapy
Acetylgalactosamine/analogs & derivatives ; Humans ; Pyrrolidines ; Quality of Life
Czasopismo naukowe
Tytuł:
Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease.
Autorzy:
Guddati AK; Division of Hematology and Oncology, Georgia Cancer Center, Augusta University, Augusta, Georgia.
Rosovsky RP; Division of Hematology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Van Cott EM; Department of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Kuter DJ; Division of Hematology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Pokaż więcej
Źródło:
International journal of laboratory hematology [Int J Lab Hematol] 2019 Jun; Vol. 41 (3), pp. 325-330. Date of Electronic Publication: 2019 Feb 08.
Typ publikacji:
Journal Article
MeSH Terms:
Deamino Arginine Vasopressin/*therapeutic use
von Willebrand Disease, Type 1/*blood
von Willebrand Disease, Type 1/*drug therapy
Adult ; Biomarkers ; Blood Coagulation ; Blood Coagulation Factors ; Blood Coagulation Tests/methods ; Deamino Arginine Vasopressin/administration & dosage ; Female ; Hemostatics/pharmacokinetics ; Hemostatics/therapeutic use ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Time Factors ; Treatment Outcome ; von Willebrand Disease, Type 1/diagnosis ; von Willebrand Factor
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies